Innate Pharma Company Top Insiders

Innate Pharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.043) % which means that it has lost $0.043 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1731) %, meaning that it generated substantial loss on money invested by shareholders. Innate Pharma's management efficiency ratios could be used to measure how well Innate Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Innate Pharma has a total of 80.21 Million outstanding shares. Innate Pharma secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in pink sheets such as Innate Pharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Innate Pharma, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Innate Pharma Workforce Comparison

The company has Profit Margin (PM) of (0.4) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.33) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.33.

Innate Pharma Benchmark Summation

Innate Pharma Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Innate Pharma often depends on how effective the management is. Innate Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Innate management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Innate management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.